ClinicalTrials.gg
CompletedNCT05905913Updated Mar 15, 2024

FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects

A Phase 1 interventional study of ANT3310 and ANT3310-placebo in Healthy Volunteers, sponsored by Antabio. Completed at 1 site in France. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Antabio · Phase 1, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and tolerability of single and multiple intravenous ascending doses of ANT3310, a novel, specific, competitive inhibitor of serine β-lactamases, alone and in combination with meropenem in healthy subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Antabio is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  • Participant capable of giving signed
  • use by women or men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Participants are overtly healthy as determined by a medical evaluation including medical history without pathologies, physical examination, vital signs, assessment, and clinical laboratory result
  • ≥ 90 mL/min and \< 160 mL/min for males or \< 150 mL/min for females
  • Body weight within 50.0 and 100.0 kg and within 18.0 and 30.0 kg/m2

Main Exclusion Criteria:

  • History of any clinically-relevant gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrine, haematologic, neuromuscular or allergic disease(s), metabolic disorder, cancer, cirrhosis, significant acute infection, local infection within 2 weeks of dose administration,
  • ECG: any history of clinically-significant ECG abnormalities, an uninterpretable ECG, or any of ECG abnormalities, unless considered not significant by the Investigator
  • Abnormalities in clinical chemical, haematological, or coagulation variables considered medically relevant by the Investigator,
  • Positive urine drug screen, positive breathalyzer for alcohol
  • Positive results in any of the following virology tests: -1 and -2 antibodies, , and anti- virus antibody
  • Positive SARS-CoV-2 antigen test
  • Women who are pregnant or nursing,
  • Donation or loss of over 500 mL of blood within sixty days prior to the first study drug administration,

Part C with co-administration of meropenem:

  1. History of epilepsy (or known seizure disorder), brain lesions or other significant neurological disorders,
  2. Known history of clinically-significant or urticaria, or severe allergic reaction to β-lactam antibiotics,
  3. History of Gilbert syndrome,
  4. History of any severe antibiotic-associated superinfections,
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Part A: Single Intravenous Ascending Dose of ANT3310

    Drug: ANT3310

  • Placebo comparator
    Part A: Single Intravenous Dose of Matching placebo

    Drug: ANT3310-placebo

  • Experimental
    Part B: Multiple Intravenous Ascending Doses of ANT3310

    Drug: ANT3310

  • Placebo comparator
    Part B: Multiple Intravenous Ascending Doses of Matching Placebo

    Drug: ANT3310-placebo

  • Experimental
    Part C: ANT3310 + Meropenem

    Participants will receive a single intravenous dose of ANT3310 or Meropenem in one of the 2 treatment sequences followed by the repeat administrations of ANT3310 + Meropenem.

    Drug: ANT3310 · Drug: Meropenem

  • Placebo comparator
    Part C: ANT3310 Placebo + Meropenem Placebo

    Participants will receive a single dose of ANT3310-placebo or Meropenem-placebo in one of the 2 treatment sequences followed by repeat administrations of ANT3310-placebo + Meropenem-placebo

    Drug: ANT3310-placebo · Drug: Meropenem-placebo

Interventions

  • ANT3310 will be infused over 3 hours

  • DrugANT3310-placebo

    ANT3310-placebo will be infused over 3 hours

  • ANT3310 will be infused over 3 hours every 8 hours

  • DrugANT3310-placebo

    ANT3310-placebo will be infused over 3 hours every 8 hours

  • DrugANT3310-placebo

    ANT3310-placebo will be infused over 3 hours as a single dose as part of the drug drug interaction study, then every 8 hours as part of the repeat doses study.

  • ANT3310 will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.

  • Meropenem will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.

  • DrugMeropenem-placebo

    Meropenem-placebo will be infused over 3 hours as a single dose as part of the drug-drug interaction study, then every 8 hours as part of the repeat doses study.

06

What researchers measure

Primary outcomes

  1. Number and severity of Treatment Emergent Adverse Events (TEAE) to evaluate the safety and tolerability profile of single and multiple intravenous ascending doses of ANT3310 alone (Part A and B) and in combination with meropenem (Part C)

    Percentage of subjects who experience at least one TEAE, including abnormalities in vital signs, physical examinations, laboratory safety tests and ECG, by seriousness, intensity, and relatedness

    Time frame: up to 11 days

Secondary outcomes

  1. Part A (SAD): Maximum Plasma Concentration (Cmax) of single i.v. ascending doses of ANT3310 alone

    Pharmacokinetic parameter of ANT3310 in plasma

    Time frame: 24 hours

  2. Part A (SAD): Area under the concentration time curve (AUC) of single i.v. ascending doses of ANT3310 alone

    Pharmacokinetic parameter of ANT3310 in plasma

    Time frame: 24 hours

  3. Part A (SAD): Time to maximum plasma concentration (Tmax) of single i.v. ascending doses of ANT3310 alone

    Pharmacokinetic parameter of ANT3310 in plasma

    Time frame: 24 hours

  4. Part A (SAD): Half-time (t1/2) of single i.v. ascending doses of ANT3310 alone

    Pharmacokinetic parameter of ANT3310 in plasma

    Time frame: 24 hours

  5. Part B (MAD): Maximum Plasma Concentration (Cmax) of multiple i.v. ascending doses of ANT3310 alone

    Pharmacokinetic parameter of ANT3310 in plasma

    Time frame: Day 1, Day 7

  6. Part B (MAD): Area under the concentration time curve (AUC) of multiple i.v. ascending doses of ANT3310 alone

    Pharmacokinetic parameter of ANT3310 in plasma

    Time frame: Day 1, Day 7

  7. Part B (MAD): Time to maximum plasma concentration (Tmax) of multiple i.v. ascending doses of ANT3310 alone

    Pharmacokinetic parameter of ANT3310 in plasma

    Time frame: Day 1, Day 7

  8. Part C (DDI and combination): Maximum Plasma Concentration (Cmax) of a single i.v. dose of ANT3310 and meropenem

    Pharmacokinetic parameter of ANT3310 and meropenem in plasma

    Time frame: Day 1, Day 3, Day 5

  9. Part C (DDI and combination): Area under the concentration time curve (AUC) of a single i.v. dose of ANT3310 and meropenem

    Pharmacokinetic parameter of ANT3310 and meropenem in plasma

    Time frame: Day 1, Day 3, Day 5

  10. Part C (DDI and combination): Time to maximum plasma concentration (Tmax) of a single i.v. dose of ANT3310 and meropenem

    Pharmacokinetic parameter of ANT3310 and meropenem in plasma

    Time frame: Day 1, Day 3, Day 5

  11. Part C (DDI and combination): Maximum Plasma Concentration (Cmax) of multiple i.v. dose of ANT3310 co-administered with meropenem

    Pharmacokinetic parameter of ANT3310 and meropenem in plasma

    Time frame: Day 11

  12. Part C (DDI and combination): Area under the concentration time curve (AUC) of multiple i.v. dose of ANT3310 co-administered with meropenem

    Pharmacokinetic parameter of ANT3310 and meropenem in plasma

    Time frame: Day 11

  13. Part C (DDI and combination): Time to maximum plasma concentration (Tmax) of multiple i.v. dose of ANT3310 co-administered with meropenem

    Pharmacokinetic parameter of ANT3310 and meropenem in plasma

    Time frame: Day 11

07

Study locations

1 site
  • Biotrial
    Rennes, 35042, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Jan 2024, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2023
First posted
Jun 15, 2023
StartActual
Apr 12, 2023
Primary completionActual
Jan 5, 2024
CompletionActual
Jan 5, 2024
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05905913
Lead sponsor
Antabio
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Apr 12, 2023
Primary completion
Jan 5, 2024
Completion
Jan 5, 2024
Last update
Mar 15, 2024

Study contacts

Sophie Hays, MD
principal investigator · Biotrial

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pilabactam sodium

Start the discussion